Our telehealth-first model removes the barriers of waiting rooms and in-person visits, but it maintains the high standards of medical supervision you deserve
Abdel-Haq R, Schlachetzki JC, Boktor JC, Cantu-Jungles TM, Thron T, Zhang M, et al
Safety & Regulatory Status PT-141: FDA-Approved PT-141 (bremelanotide) completed the full FDA approval pathway: Two Phase III trials (RECONNECT) with 1,267 women Established safety profile over 24-week treatment periods Known drug interactions (minimal low CYP enzyme metabolism) Maximum frequency: one dose per 24 hours MT-2: Unregulated MT-2 has only completed Phase I clinical trials (safety/tolerability in small groups): No Phase II or III efficacy/safety data for tanning All available product is unregulated research chemical No standardized manufacturing or quality control Purity varies significantly between sources This regulatory gap is the single biggest difference in risk profile between these peptides
Reading the ingredient list is crucial
This gap has presumably resulted in the four times difference in prescription rates between White and Black patients
Because IV therapy bypasses the digestive system, many clients feel increased energy and mental clarity almost immediately